<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751140</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15441</org_study_id>
    <secondary_id>10718</secondary_id>
    <nct_id>NCT00751140</nct_id>
  </id_info>
  <brief_title>Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection</brief_title>
  <official_title>Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to show that performing a lymph node dissection may detect occult
      nodal metastasis in this patient population whereby providing important diagnostic
      information, with potential therapeutic benefits in patients with isolated nodal metastases.

      In case of urothelial carcinoma of the upper urinary tract (a cancer originating from the
      inner lining of the urinary tract) requiring the removal of the kidney, ureter, and cuff of
      bladder (a surgical termed a nephroureterectomy). Previous studies in urothelial carcinoma of
      the bladder, have shown that doing a lymph node dissection (surgically removing the lymph
      nodes) may improve survival, or at least give an idea of what patients may need chemotherapy
      (drugs to control the cancer cells that are outside the kidney-ureter) earlier (before the
      nodes are enlarged in the imaging studies).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will have a nephroureterectomy (taking the kidney and the ureter). Investigators
      will also be doing a lymph node dissection (taking the patient's lymph nodes in the same side
      of the kidney) to look for malignancy outside of the kidney and ureter. The lymph nodes will
      be sent to pathology for review.

      Study visits will be scheduled 10 to 14 days after surgery for removal of stitches and
      analysis of the patient's pathology report.

      The following procedures will be done:

        -  History and physical examination, urinary cytology (test to look for malignant cells in
           the urine) and surveillance cystoscopy (procedure to look inside the urethra and bladder
           which is performed in the office under local anesthesia) every 3 months for the first 2
           years after treatment, every 6 months for the next 2 years and yearly thereafter if the
           patient is free from recurrence.

        -  Radiographic studies including chest x-ray and abdomino-pelvic computed tomography (CAT
           scans) will be performed every 6 months for the first 2 years and then yearly
           thereafter.

        -  Bone scan (special imaging study to look for cancer spread in bone) in case of bone pain
           or elevated alkaline phosphatase level.

      After surgery patients will be followed every 3 months for the first 2 years after treatment,
      every 6 months for the next 2 years and yearly thereafter if they are free from recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pathologically Proven Lymph Node Metastasis</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The number of participants having pathologically proven lymph node metastasis at the time of radical nephroureterectomy (RNU) and modified retroperitoneal lymph node dissection (RPLND).
The primary endpoint is the detection via lymph node dissection of pathological node positive urothelial carcinoma in patients treated with open or laparoscopic nephroureterectomy for upper tract urothelial cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical Outcomes: Mean Lymph Node Count</measure>
    <time_frame>2 years</time_frame>
    <description>The mean (range) total lymph node count and lymph node count per procedure category. Between 2009 and 2011, patients with suspected upper urinary tract urothelial carcinoma (UUT-UC) underwent open, laparoscopic, or robot-assisted radical nephroureterectomy (RNU) with modified retroperitoneal lymph node dissection (RPLND).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cancer of the Urinary Tract</condition>
  <arm_group>
    <arm_group_label>Lymph Node Dissection at Time of Nephroureterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymph Node Dissection</intervention_name>
    <description>The lymph nodes will be sent to pathology for review.</description>
    <arm_group_label>Lymph Node Dissection at Time of Nephroureterectomy</arm_group_label>
    <other_name>nephroureterectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected transitional cell carcinoma of the upper urinary tract which
             are deemed surgical candidates

          -  Negative visible retroperitoneal or peri-hilar lymphadenopathy on pre-operative
             radiographic studies. Defined as the absence of suspicious abdominal, retroperitoneal,
             or pelvic lymphadenopathy (defined as &gt; 1 centimeter [cm]) on pre-operative
             radiographic imaging (Abdominal and pelvic computed tomography [CT] or magnetic
             resonance imaging [MRI] if CT contraindicated). Imaging studies can be done at Moffitt
             or at a local facility of the patient's choice. All imaging studies are going to be
             reviewed at Moffitt.

          -  Note: Nodal involvement will depend on the size of the lymph node enlargement; usually
             nodes of more than 2 cm are associated with malignancy. With a threshold of 1cm, false
             negative rates for microscopic metastases are low (4%) and false positive rates are
             between 3 to 43% according to the literature. Because the aim of the study will be to
             perform a lymph node dissection in patients with non-metastatic disease based on
             pre-operative evaluation, 1 cm will be the threshold used. Nodes of more than 1 cm
             will be considered positive and those patients will be excluded as is mentioned in the
             protocol. Biopsy will not be included as part of the protocol as those potential
             patients with nodes of more than 1 cm will be excluded.

          -  No other suspected sites of metastasis on pre-operative radiographic imaging

        Exclusion Criteria:

          -  Patients with visible lymph node metastasis on pre-operative radiographic studies.
             Defined as &gt;1cm abdominal, retroperitoneal or pelvic lymphadenopathy

          -  Patients with suspected sites of distant metastasis on pre-operative imaging.
             (Patients with suspected bony metastases will require a bone scan.)

          -  Patients with suspected transitional cell carcinoma of the upper urinary tract with
             significant comorbidities making them non-surgical candidates

          -  Patients with non-transitional cell carcinoma of the upper urinary tract will be
             excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Spiess, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/22564727</url>
    <description>Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma.</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2012.11170.x/full</url>
    <description>Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2013</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgical candidates</keyword>
  <keyword>upper urinary tract</keyword>
  <keyword>urothelial carcinoma</keyword>
  <keyword>lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sample: Up to 30 patients with a diagnosis of urothelial carcinoma of the upper urinary tract in the absence of pre-operative (radiographic) lymphadenopathy or other areas of suspected metastatic disease were planned to serve as the investigators' study sample population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lymph Node Dissection at Time of Nephroureterectomy</title>
          <description>A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
Lymph Node Dissection : The lymph nodes will be sent to pathology for review.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>benign angioma excluded from analysis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lymph Node Dissection at Time of Nephroureterectomy</title>
          <description>A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
Lymph Node Dissection : The lymph nodes will be sent to pathology for review.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="42" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pathologically Proven Lymph Node Metastasis</title>
        <description>The number of participants having pathologically proven lymph node metastasis at the time of radical nephroureterectomy (RNU) and modified retroperitoneal lymph node dissection (RPLND).
The primary endpoint is the detection via lymph node dissection of pathological node positive urothelial carcinoma in patients treated with open or laparoscopic nephroureterectomy for upper tract urothelial cancer.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>All evaluable participants. On histopathological review, one patient had a benign angioma and was excluded from the final data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lymph Node Dissection at Time of Nephroureterectomy</title>
            <description>A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
Lymph Node Dissection : The lymph nodes will be sent to pathology for review.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathologically Proven Lymph Node Metastasis</title>
          <description>The number of participants having pathologically proven lymph node metastasis at the time of radical nephroureterectomy (RNU) and modified retroperitoneal lymph node dissection (RPLND).
The primary endpoint is the detection via lymph node dissection of pathological node positive urothelial carcinoma in patients treated with open or laparoscopic nephroureterectomy for upper tract urothelial cancer.</description>
          <population>All evaluable participants. On histopathological review, one patient had a benign angioma and was excluded from the final data analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Outcomes: Mean Lymph Node Count</title>
        <description>The mean (range) total lymph node count and lymph node count per procedure category. Between 2009 and 2011, patients with suspected upper urinary tract urothelial carcinoma (UUT-UC) underwent open, laparoscopic, or robot-assisted radical nephroureterectomy (RNU) with modified retroperitoneal lymph node dissection (RPLND).</description>
        <time_frame>2 years</time_frame>
        <population>Total Participants and Participants Per Procedure Category</population>
        <group_list>
          <group group_id="O1">
            <title>Total Lymph Node Count</title>
            <description>Total Lymph Node Count for All Participants</description>
          </group>
          <group group_id="O2">
            <title>Open RNU Lymph Node Count</title>
            <description>Lymph Node Count for Open RNU Procedure Group</description>
          </group>
          <group group_id="O3">
            <title>Laparoscopic RNU Lymph Node Count</title>
            <description>Lymph Node Count for Laparoscopic RNU Procedure Group</description>
          </group>
          <group group_id="O4">
            <title>Robot-assisted RNU Lymph Node Count</title>
            <description>Lymph Node Count for Robot-assisted RNU Procedure Group</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Outcomes: Mean Lymph Node Count</title>
          <description>The mean (range) total lymph node count and lymph node count per procedure category. Between 2009 and 2011, patients with suspected upper urinary tract urothelial carcinoma (UUT-UC) underwent open, laparoscopic, or robot-assisted radical nephroureterectomy (RNU) with modified retroperitoneal lymph node dissection (RPLND).</description>
          <population>Total Participants and Participants Per Procedure Category</population>
          <units>Lymph Nodes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="17"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="17"/>
                    <measurement group_id="O3" value="8" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="O4" value="6" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lymph Node Dissection at Time of Nephroureterectomy</title>
          <description>A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
Lymph Node Dissection : The lymph nodes will be sent to pathology for review.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Clavien Grading</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chylous leak requiring surgical exploration - Grade IIIb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Clavien Grading</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Transfusion - Grade II</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Postoperative ileus - Grade II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chylous leak managed conservatively - Grade II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size was small because it was a single institution study. It was thus underpowered to achieve a cancer-specific endpoint pertaining to the oncological merit of performing a modified RPLND in the context of UUT-UC.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Philippe E. Spiess, M.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-8343</phone>
      <email>philippe.spies@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

